Rita Chiari
Expertise in
5
conditions

Rita Chiari

Pesaro, IT 
Expertise in
5
conditions
Pesaro, IT 

Overview

Rita Chiari practices practicing medicine in Pesaro, Italy.

Ms. Chiari is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 179 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Pesaro, Italy
Other Locations
Marche, Italy
Urbino, Italy
Perugia, Italy
Fano, Italy
Padova, Italy
Italy
Monselice, 35043, Italy
Varese, Italy
St. Andrea Hospital, Rome, Italy
St. Salvatore Hospital, L'aquila, Italy
Via S. Rocco 8, Piove Di Sacco-piovega, 35028, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
Enrollment Status: Unknown
Publish Date: October 03, 2022
Intervention Type: Other, Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
Enrollment Status: Unknown
Publish Date: April 03, 2020
Intervention Type: Drug
Study Drugs: Netupitant+Palonosetron, Dexamethasone
Study Phase: Phase 3
View 4 Less Clinical Trials

179 Total Publications

Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2026

Frequently Asked Questions about Rita Chiari

Is Rita Chiari a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Rita Chiari is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rita Chiari participate in research or clinical trials?

Yes. Rita Chiari has published 179 articles and abstracts on conditions like Lung Cancer. You can view a list of Rita Chiari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Chiari's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile